Just...

Just published,

--------------------
http://www.smh.com.au/news/business/money/investment/where-the-pulse-beats-strongly/2009/06/01/1243708407914.html?page=fullpage#contentSwap1

----------------

Biotech and healthcare analyst at Shaw Stockbroking, Matthijs Smith, says: "A company like Biota Holdings [developer of the flu drug Relenza] is in a good position. In its latest half-year report it had something like $55 million in the bank and there will be revenues for the next few years coming in from Relenza. It is not in bad shape at all.

"Other biotech companies like Pharmaxis, Peplin, Acrux and Nanosonics have all developed new products and are well cashed up. Equally, on the other side, there is a whole bunch of much smaller companies that have less than six months' money in the bank. They are in quite a precarious position.